^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + BRAF V600K

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1d
    Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis. (PubMed, Cancers (Basel))
    Background/Objective: Dabrafenib and trametinib (D + T) have been approved for the treatment of stage III melanoma with BRAF V600E V600K mutations in an adjuvant setting, based on the results from the COMBI-AD trial. Similarly, the median OS was not reached, with OS rates of 96.4% at 12 months and 92.5% at 24 months. D + T achieved an RFS benefit, with effects sustained beyond the treatment period, indicating positive outcomes in this patient population.
    Observational data • Retrospective data • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    2ms
    Ursolic acid interaction with transcription factors BRAF, V600E, and V600K: a computational approach towards new potential melanoma treatments. (PubMed, J Mol Model)
    Due to the relevance of the BRAFV600E mutation, inhibitors to this kinase have been developed, vemurafenib-OMe and dabrafenib. Ligand-protein interactions were evaluated using Schrödinger-Maestro program, LigPlot + , and PLIP (protein-ligand interaction profiler). Finally, all of the protein figures presented in this article were made in the PyMOL program.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF wild-type • BRAF V600 wild-type • BRAF V600E + BRAF V600K
    |
    Zelboraf (vemurafenib) • Tafinlar (dabrafenib)
    7ms
    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings (clinicaltrials.gov)
    P=N/A, N=1, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Dec 2023 | Trial primary completion date: May 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Real-world evidence • Real-world • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    10ms
    Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma (clinicaltrials.gov)
    P1; Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Combination therapy • Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    MSK-IMPACT
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • phenformin
    10ms
    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2, N=68, Suspended, ImmVira Pharma Co. Ltd | Phase classification: P2a --> P2 | Trial completion date: Jan 2026 --> Jan 2027 | Not yet recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K
    |
    Cotellic (cobimetinib) • T3011
    12ms
    Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=280, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    1year
    Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1; Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    cobas® 4800 BRAF V600 Mutation Test
    |
    Tafinlar (dabrafenib) • lapatinib
    over1year
    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence • Real-world • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    over1year
    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings (clinicaltrials.gov)
    P=N/A, N=1, Not yet recruiting, Pfizer
    New trial • Real-world evidence • Real-world • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    over1year
    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2a, N=68, Not yet recruiting, ImmVira Pharma Co. Ltd | Initiation date: Mar 2023 --> Jun 2023
    Trial initiation date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K
    |
    Cotellic (cobimetinib) • T3011